On December 3, 2025, Aurinia Pharmaceuticals (AUPH), a biopharmaceutical company, experienced a crucial update from analyst Joseph Schwartz of Leerink Partners. The firm downgraded its rating on AUPH stock from "Outperform" to "Market Perform". Despite the downgrade, the price target for Aurinia Pharmaceuticals has been raised from $15.00 to $16.00, marking a 6.67% increase.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.